Lucy Xu is a local partner in the Mergers and Acquisitions Practice Group.
Lucy has experience advising multinational companies on a range of cross border mergers, acquisitions, divestitures and private equity transactions. In addition, Lucy has experience advising venture capital funds on fund investment issues, as well as advising companies, including start-up and pre-IPO stage companies, in their fundraising activities.
Lucy also represents multinational and foreign corporates in their investment projects and trade activities in China. These matters cover a wide range of areas, including cross-border M&A, China inbound investment, corporate restructuring and other commercial transactions. Lucy has advised clients from a wide range of industries with their investments and operations in China such as media, machinery, education, health care, food processing, real estate, computer software and equipment and hotel management.
In addition to her M&A and corporate experience, Ms. Xu has experience with Chinese antitrust issues involving antitrust investigations and merger clearance in China. She also regularly provides compliance and anti-trust training to our corporate clients, such as Johnson Matthey, JM Smucker and Century Aluminum.
School of Law
Johnson Matthey Plc, a British chemicals company (LSE: JMAT), in its acquisition of the battery materials manufacturing business in Changzhou, China from A123 Systems (China) by way of asset purchase.
Shenzhen Hepalink Pharmaceutical Co., Ltd. and its US subsidiary, Hepalink USA Inc., in its US$337.5 million acquisition of 100 percent of the equity interest of Scientific Protein Laboratories, LLC, one of the leading global, independent manufacturers and suppliers of active pharmaceutical ingredients.
The J.M. Smucker Company in the US$35 million acquisition of a non-controlling equity position in one of the leading Chinese manufacturers for oatmeal products. This was J.M. Smucker Company's first acquisition in China involving a series of very complicated restructuring work inside China.
Lilly Asian Ventures, in its various venture capital and private equity investments in Chinese pharmaceutical companies.
Johnson Matthey in its acquisition of a cathode material manufacturing facility in China from A123 Systems.